307 related articles for article (PubMed ID: 17703180)
1. Cannabis; adverse effects from an oromucosal spray.
Scully C
Br Dent J; 2007 Sep; 203(6):E12; discussion 336-7. PubMed ID: 17703180
[TBL] [Abstract][Full Text] [Related]
2. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis.
Rog DJ; Nurmikko TJ; Friede T; Young CA
Neurology; 2005 Sep; 65(6):812-9. PubMed ID: 16186518
[TBL] [Abstract][Full Text] [Related]
4. Cannabis derivatives and pain. A small role for delta9-tetrahydrocannabinol (THC) in some forms of multiple sclerosis.
Prescrire Int; 2009 Oct; 18(103):226. PubMed ID: 19882800
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use.
Schoedel KA; Chen N; Hilliard A; White L; Stott C; Russo E; Wright S; Guy G; Romach MK; Sellers EM
Hum Psychopharmacol; 2011 Apr; 26(3):224-36. PubMed ID: 21671456
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Conte A; Bettolo CM; Onesti E; Frasca V; Iacovelli E; Gilio F; Giacomelli E; Gabriele M; Aragona M; Tomassini V; Pantano P; Pozzilli C; Inghilleri M
Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
[TBL] [Abstract][Full Text] [Related]
7. THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
Sastre-Garriga J; Vila C; Clissold S; Montalban X
Expert Rev Neurother; 2011 May; 11(5):627-37. PubMed ID: 21456949
[TBL] [Abstract][Full Text] [Related]
8. Combined cannabinoid therapy via an oromucosal spray.
Perez J
Drugs Today (Barc); 2006 Aug; 42(8):495-503. PubMed ID: 16969427
[TBL] [Abstract][Full Text] [Related]
9. Abuse potential and psychoactive effects of δ-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine.
Robson P
Expert Opin Drug Saf; 2011 Sep; 10(5):675-85. PubMed ID: 21542664
[TBL] [Abstract][Full Text] [Related]
10. Cannabis derivatives therapy for a seronegative stiff-person syndrome: a case report.
Vicente-Valor MI; Garcia-Llopis P; Mejia Andujar L; Antonino de la Camara G; García del Busto N; Lopez Tinoco MJ; Quintana Vergara B; Peiro Vilaplana C; Dominguez Moran JA; Sánchez Alcaraz A
J Clin Pharm Ther; 2013 Feb; 38(1):71-3. PubMed ID: 22726074
[TBL] [Abstract][Full Text] [Related]
11. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine.
Russo EB; Guy GW; Robson PJ
Chem Biodivers; 2007 Aug; 4(8):1729-43. PubMed ID: 17712817
[TBL] [Abstract][Full Text] [Related]
12. Advances in the management of multiple sclerosis spasticity: recent clinical trials.
Fernández O
Eur Neurol; 2014; 72 Suppl 1():9-11. PubMed ID: 25278117
[TBL] [Abstract][Full Text] [Related]
13. Sativex for the management of multiple sclerosis symptoms.
Perras C
Issues Emerg Health Technol; 2005 Sep; (72):1-4. PubMed ID: 16317825
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice.
Vermersch P; Trojano M
Eur Neurol; 2016; 76(5-6):216-226. PubMed ID: 27732980
[TBL] [Abstract][Full Text] [Related]
15. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?].
Trebst C; Stangel M
Fortschr Neurol Psychiatr; 2005 Aug; 73(8):463-9. PubMed ID: 16052440
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
Koehler J; Feneberg W; Meier M; Pöllmann W
Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
[TBL] [Abstract][Full Text] [Related]
17. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis.
Collin C; Davies P; Mutiboko IK; Ratcliffe S;
Eur J Neurol; 2007 Mar; 14(3):290-6. PubMed ID: 17355549
[TBL] [Abstract][Full Text] [Related]
19. Medicinal cannabis extracts for the treatment of multiple sclerosis.
Smith PF
Curr Opin Investig Drugs; 2004 Jul; 5(7):727-30. PubMed ID: 15298068
[TBL] [Abstract][Full Text] [Related]
20. The effects of cannabis, cannabinoids, and their administration routes on pain control efficacy and safety: A systematic review and network meta-analysis.
Rabgay K; Waranuch N; Chaiyakunapruk N; Sawangjit R; Ingkaninan K; Dilokthornsakul P
J Am Pharm Assoc (2003); 2020; 60(1):225-234.e6. PubMed ID: 31495691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
